Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
Sunshine Biopharma (NASDAQ:SBFM) has announced that its Canadian subsidiary, Nora Pharma, has acquired rights to two gastrointestinal drugs in the Canadian market, with one already launched and the second planned for launch within 9 months.
The first launched drug is Prucalopride, a generic version of Resotran®, available in 1mg and 2mg tablet strengths. The drug treats chronic idiopathic constipation in adult women when laxatives are ineffective by stimulating 5-HT4 receptors to enhance gastrointestinal motility.
Both drugs target the chronic idiopathic constipation submarket within Canada's $200 million CAD gastrointestinal market. The sector is projected to grow at a 4.64% CAGR from 2024 to 2034, driven by increasing gastrointestinal disorder prevalence and treatment awareness.
Sunshine Biopharma (NASDAQ:SBFM) ha annunciato che la sua filiale canadese, Nora Pharma, ha acquisito i diritti su due farmaci gastrointestinali nel mercato canadese, con uno già lanciato e il secondo previsto per il lancio entro 9 mesi.
Il primo farmaco lanciato è Prucalopride, una versione generica di Resotran®, disponibile in compresse da 1 mg e 2 mg. Questo farmaco tratta la stitichezza cronica idiopatica nelle donne adulte quando i lassativi risultano inefficaci, stimolando i recettori 5-HT4 per migliorare la motilità gastrointestinale.
Entrambi i farmaci mirano al sottosegmento della stitichezza cronica idiopatica all'interno del mercato gastrointestinale canadese da $200 milioni CAD. Si prevede che il settore crescerà a un CAGR del 4,64% dal 2024 al 2034, sostenuto dall'aumento della prevalenza dei disturbi gastrointestinali e della consapevolezza sul trattamento.
Sunshine Biopharma (NASDAQ:SBFM) ha anunciado que su filial canadiense, Nora Pharma, ha adquirido los derechos de dos medicamentos gastrointestinales en el mercado canadiense, con uno ya lanzado y el segundo programado para lanzarse en 9 meses.
El primer medicamento lanzado es Prucalopride, una versión genérica de Resotran®, disponible en tabletas de 1 mg y 2 mg. Este medicamento trata el estreñimiento idiopático crónico en mujeres adultas cuando los laxantes son ineficaces, estimulando los receptores 5-HT4 para mejorar la motilidad gastrointestinal.
Ambos medicamentos se dirigen al submercado del estreñimiento idiopático crónico dentro del mercado gastrointestinal canadiense de $200 millones CAD. Se proyecta que el sector crecerá a un CAGR del 4,64% desde 2024 hasta 2034, impulsado por el aumento de la prevalencia de trastornos gastrointestinales y la concienciación sobre el tratamiento.
Sunshine Biopharma (NASDAQ:SBFM)는 캐나다 자회사인 Nora Pharma가 캐나다 시장에서 두 가지 위장약에 대한 권리를 취득했다고 발표했습니다. 그 중 하나는 이미 출시되었고, 두 번째는 9개월 이내에 출시될 예정입니다.
첫 번째 출시된 약물은 프루칼로프리드로, Resotran®의 제네릭 버전이며 1mg 및 2mg 정제로 제공됩니다. 이 약물은 변비약이 효과가 없을 때 성인 여성의 만성 특발성 변비를 치료하며, 5-HT4 수용체를 자극하여 위장 운동성을 향상시킵니다.
두 약물 모두 캐나다의 $200 백만 CAD 위장 시장 내 만성 특발성 변비 하위 시장을 목표로 하고 있습니다. 이 부문은 2024년부터 2034년까지 4.64% CAGR로 성장할 것으로 예상되며, 이는 위장 질환의 유병률 증가와 치료 인식 향상에 의해 촉진될 것입니다.
Sunshine Biopharma (NASDAQ:SBFM) a annoncé que sa filiale canadienne, Nora Pharma, a acquis les droits de deux médicaments gastro-intestinaux sur le marché canadien, dont l'un est déjà lancé et le second est prévu pour lancement dans les 9 mois.
Le premier médicament lancé est Prucalopride, une version générique de Resotran®, disponible en comprimés de 1 mg et 2 mg. Ce médicament traite la constipation idiopathique chronique chez les femmes adultes lorsque les laxatifs ne sont pas efficaces, en stimulant les récepteurs 5-HT4 pour améliorer la motilité gastro-intestinale.
Les deux médicaments ciblent le sous-marché de la constipation idiopathique chronique dans le marché gastro-intestinal canadien de $200 millions CAD. Le secteur devrait croître à un TAC de 4,64% de 2024 à 2034, soutenu par l'augmentation de la prévalence des troubles gastro-intestinaux et la sensibilisation au traitement.
Sunshine Biopharma (NASDAQ:SBFM) hat angekündigt, dass ihre kanadische Tochtergesellschaft, Nora Pharma, die Rechte an zwei gastrointestinalen Medikamenten auf dem kanadischen Markt erworben hat, wobei eines bereits auf dem Markt ist und das zweite innerhalb von 9 Monaten eingeführt werden soll.
Das erste eingeführte Medikament ist Prucalopride, eine generische Version von Resotran®, erhältlich in Tablettenstärken von 1 mg und 2 mg. Das Medikament behandelt chronische idiopathische Verstopfung bei erwachsenen Frauen, wenn Abführmittel nicht wirksam sind, indem es die 5-HT4-Rezeptoren stimuliert, um die gastrointestinalen Motilität zu verbessern.
Beide Medikamente zielen auf das Subsegment der chronischen idiopathischen Verstopfung innerhalb des kanadischen $200 Millionen CAD gastrointestinalen Marktes ab. Es wird prognostiziert, dass der Sektor von 2024 bis 2034 mit einer CAGR von 4,64% wachsen wird, angetrieben durch die zunehmende Prävalenz gastrointestinaler Störungen und das Bewusstsein für Behandlungen.
- Expansion into $200M CAD gastrointestinal market
- First drug already launched with second launch planned within 9 months
- Target market growing at 4.64% CAGR (2024-2034)
- Additional product launches planned for remainder of 2025
- initial market to adult women with chronic idiopathic constipation
- Competing with established brands like Resotran and Motegrity
Insights
Sunshine Biopharma's strategic acquisition of rights to two gastrointestinal drugs represents a significant market expansion opportunity for this small-cap pharmaceutical company. The company has already launched Prucalopride, a 5-HT4 receptor agonist that increases gastrointestinal motility for treating chronic idiopathic constipation in adult women unresponsive to conventional laxatives.
The entry into the Canadian gastrointestinal market, valued at
This move aligns with classic pharmaceutical portfolio diversification strategy - launching approved generic medications presents lower regulatory risks and faster revenue realization compared to novel drug development. With Prucalopride already available in 1mg and 2mg formulations and a second product planned within 9 months, SBFM is establishing a foothold in the growing gastrointestinal therapeutic area.
The CEO's statement about additional product launches in 2025 suggests this acquisition is part of a broader growth strategy rather than an isolated opportunity. For investors, this structured approach to expanding the product portfolio into established markets with approved drugs represents a more immediate path to potential revenue growth than the company's ongoing research programs alone.
The acquisition of rights to two gastrointestinal drugs marks a pivotal revenue diversification opportunity for Sunshine Biopharma. With the first product already launched and a second expected within 9 months, this moves the company beyond pure research and development into commercialization with immediate revenue potential.
The financial significance becomes apparent when examining the scale: SBFM, with its
The chronic idiopathic constipation market's
Generic pharmaceutical strategies often focus on portfolio breadth across multiple indications to create revenue diversity and stability. The CEO's indication of additional product launches in 2025 suggests this acquisition is one component of a broader commercialization strategy. For a nano-cap pharmaceutical company, this represents a balanced approach combining near-term revenue generation from approved generics with longer-horizon research programs in oncology and antivirals mentioned in the company description.
The timing appears opportunistic, targeting a market segment experiencing increasing diagnosis rates and treatment awareness, potentially lowering marketing costs for patient education and physician outreach.
FORT LAUDERDALE, FL / ACCESS Newswire / March 10, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has acquired the rights to two gastrointestinal drugs and already launched one. The second is planned to be launched in the next 9 months.
The newly launched drug is Prucalopride, a generic version of Resotran®. In the United States, Prucalopride is sold under the brand name, Motegrity®. Prucalopride is indicated for the treatment of chronic idiopathic constipation in adult women for whom laxatives do not provide adequate relief. Prucalopride works by selectively stimulating the 5-HT4 receptors in the gastrointestinal tract. This action promotes cholinergic and non-adrenergic neurotransmission by enteric neurons, leading to increased peristaltic reflex, intestinal secretions, and overall gastrointestinal motility.
Nora Pharma's Prucalopride is available in blisters packs of 28 tablets for the Canadian market in strengths of 1 mg and 2 mg.
Both Prucalopride and the second drug Sunshine Biopharma is planning to launch by year end are in the chronic idiopathic constipation submarket of the total gastrointestinal market currently recording sales in excess of
According to BioSpace, the chronic idiopathic constipation market is expected to grow at a Compound Annual Growth Rate (CAGR) of
"The gastrointestinal market is poised to benefit from advancements in healthcare infrastructure and the increasing availability of effective medications through various distribution channels, including ours," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "We anticipate launching additional products in the remainder of 2025," he added.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 15 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.
In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
What is the market size for Sunshine Biopharma's new gastrointestinal drugs in Canada?
When will SBFM launch its second gastrointestinal drug in Canada?
What is the projected growth rate for the chronic idiopathic constipation market?
What dosage forms are available for SBFM's Prucalopride in Canada?
How does SBFM's Prucalopride work to treat chronic constipation?
